J&J buys into Bristol-Myers cardiovascular disease program

Johnson & Johnson has bought into Bristol-Myers Squibb’s Factor XIa inhibitor program. The deal gives J&J a stake in the development and potential commercialization of anticoagulants including phase 2-ready secondary stroke candidate BMS-986177.

• Source: Fiercebiotech
• 2,262
• April 19, 2018